TARS Q3 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119M+146.7% YoY

Gross Profit

$94M79.3% margin

Operating Income

-$15M-12.2% margin

Net Income

-$13M-10.6% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+15.6%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$16M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$535M

Total Liabilities

$199M

Stockholders' Equity

$335M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119M	$48M	+146.7%
Gross Profit	$94M	$45M	+109.7%
Operating Income	-$15M	-$25M	+42.3%
Net Income	-$13M	-$23M	+46.3%

Revenue Segments

Product

$119M100%